Proteogenetic drug response profiling elucidates targetable vulnerabilities of myelofibrosis

Proteogenetic drug response profiling elucidates targetable vulnerabilities of myelofibrosis

Abstract Myelofibrosis is a hematopoietic stem cell disorder belonging to the myeloproliferative neoplasms. Myelofibrosis patients frequently carry driver mutations in either JAK2 or Calreticulin (CALR) and have limited therapeutic options. Here, we integrate ex vivo drug response and proteotype ana...

Full description

Bibliographic Details
Main Authors: Mattheus H. E. Wildschut, Julien Mena, Cyril Dördelmann, Marc van Oostrum, Benjamin D. Hale, Jens Settelmeier, Yasmin Festl, Veronika Lysenko, Patrick M. Schürch, Alexander Ring, Yannik Severin, Michael S. Bader, Patrick G. A. Pedrioli, Sandra Goetze, Audrey van Drogen, Stefan Balabanov, Radek C. Skoda, Massimo Lopes, Bernd Wollscheid, Alexandre P. A. Theocharides, Berend Snijder
Format: Article
Language:English
Published: Nature Portfolio 2023-10-01
Series:Nature Communications
Online Access:https://doi.org/10.1038/s41467-023-42101-z

Internet

https://doi.org/10.1038/s41467-023-42101-z

Similar Items